APA (7th ed.) Citation

Vandell, A. G., Inoue, S., Dennie, J., Nagasawa, Y., Gajee, R., Pav, J., . . . Senaldi, G. (2018). Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects. Antimicrobial Agents and Chemotherapy, 62(5), . https://doi.org/10.1128/aac.02537-17

Chicago Style (17th ed.) Citation

Vandell, Alexander G., et al. "Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects." Antimicrobial Agents and Chemotherapy 62, no. 5 (2018). https://doi.org/10.1128/aac.02537-17.

MLA (9th ed.) Citation

Vandell, Alexander G., et al. "Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects." Antimicrobial Agents and Chemotherapy, vol. 62, no. 5, 2018, https://doi.org/10.1128/aac.02537-17.